LUCD - Lucid Diagnostics Inc.
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma.
- Sector
- Healthcare
- Industry
- Medical - Devices
- Market Cap
- $106.4M
- Beta
- 1.10
- 52-Week Range
- 0.9-1.629
- CEO
- Lishan Aklog
- Employees
- 72
- IPO Date
- Oct 14, 2021
- Exchange
- NASDAQ
LUCD Options Snapshot
Options pricing data for LUCD is refreshed daily after the close. When listed contracts exist, this page surfaces the latest at-the-money implied volatility, max pain strike, dealer gamma exposure (GEX), and 25-delta skew. Listed contracts and live snapshots appear once the options chain has been published by the exchange for the most recent session.
What This Page Covers
The LUCD overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.
Frequently asked LUCD overview questions
- What is LUCD?
- LUCD is the ticker symbol for Lucid Diagnostics Inc., a listed security. Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. Listed on NASDAQ. LUCD is the equity ticker shown on this page; equity options traders use the security for directional, volatility, and income strategies via the listed options chain.
- What are LUCD's key statistics?
- Lucid Diagnostics Inc. (LUCD) carries a market capitalization of $106.4M, beta of 1.10 relative to the broader market, 52-week range of 0.9-1.629. Full income statement, balance sheet, cash flow, and TTM ratio history is on the per-ticker fundamentals page; daily price history and 52-week levels are accessible from the same view. These structural inputs frame how the options market prices implied volatility around earnings windows and capital events.
- What sector or industry does LUCD belong to?
- Lucid Diagnostics Inc. operates in the Healthcare sector, in the Medical - Devices industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare LUCD's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
- How current is the LUCD data on this page?
- Options snapshots refresh after each trading session; if no snapshot is currently posted for LUCD, it usually reflects low options liquidity or a recently listed name. Company-profile fields (sector, industry, market cap, P/E, IPO date) refresh from the vendor feed nightly. Financials and earnings refresh as 10-K and 10-Q filings are parsed (typically within several business days of the actual report). FINRA microstructure data refreshes on the source's cadence (daily for short volume, bi-monthly for short interest, weekly for the OTC volume file, twice-monthly for SEC FTD).